581799-33-9

Upstream product

• 619-21-6 m-formylphenyl benzoic acid 
• 115974-96-4 (E)-3-(methoxy-3-oxoprop-1-en-1-yl)benzoic acid 

Downstream Products

• 1018674-32-2 (2E)-3-(3-{[(1S)-1-cyclohexyl-2-(cyclopentyloxy)-2-oxoethyl]carbamoyl}phenyl)acrylic acid 
• 1018674-33-3 cyclopentyl (2S)-cyclohexyl[(3-{(1E)-3-[(1-isobutoxyethoxy)amino]-3-oxoprop-1-en-1-yl}benzoyl)amino]acetate 
• 1018674-31-1 methyl (2E)-3-(3-{[(1S)-1-cyclohexyl-2-(cyclopentyloxy)-2-oxoethyl]carbamoyl}phenyl)acrylate 
• 23746-59-0 (E)-3-[3-((E)-2-methoxycarbonyl-vinyl)-phenyl]-acrylic acid methyl ester 

Relevant academic research and scientific papers

Synthesis of unsymmetrical divinylbenzenes by palladium catalyzed sequential heck reactions starting from carboxybenzenediazonium salts

Six p-, m- and o-unsymmetrical divinylbenzenes 5a, 5b, 6a, 6b, 6c and 7a are synthesized from p-, m- and o- carboxybenzenediazonium tetrafluoroborates via sequential Heck reactions in good overall yield.

CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The compounds of the invention may further act as HDAC inhibitors.

HDAC INHIBITORS

Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent =C- or =N-; W is a divalent radical -CH=CH- or CH2CH2-; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.